Anti-inflammatory effects of tiotropium in COPD: a randomised double-blind trial.

ABSTRACT:

Background

COPD is a major global health issue characterised by respiratory symptoms and exacerbations, significantly impacting mortality and quality of life. Muscarinic antagonists are known to prevent exacerbations, possibly by mitigating airway inflammation. This study evaluated the anti-inflammatory effects of tiotropium in patients with COPD by examining inflammatory protein profiles in sputum and blood, and genome-wide expression in sputum.

Methods

We conducted the prospective, double-blind, randomised controlled ANTIOFLAM trial. Patients with COPD Global Initiative for Chronic Obstructive Lung Disease stage II or worse, aged ≥40 years and a smoking history of ≥10 pack-years were included. After a 4-week washout period of inhaled corticosteroids and anticholinergics, p

SUBMITTER: van Smoorenburg LH 

PROVIDER: S-EPMC11955910 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature